Piper Sandler cuts Connect Biopharma stock price target on launch delay

Piper Sandler reduced its price target for Connect Biopharma (CNTB) to $5.00 from $7.00, citing a delayed launch timeline for rademikibart. The stock is trading at $0.64, down 74% over the past year. The company reported mixed Phase 2 trial results and plans to discuss Phase 3 programs with the FDA. Analysts have mixed price targets, ranging from $4 to $9.

Original reporting
Published Nov 17, 2026, 1:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CNTB
Bearish
medium confidence
Mentioned
$CNTB
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CNTBBearishMed
01

Why it matters

The immediate trading signal is the analyst’s lowered price target driven by a later modeled launch date, which can influence positioning in thinly traded biotech names even without a new clinical failure.

02

Market read

For CNTB, the PT cut and launch-timing downgrade are a near-term sentiment catalyst, while FDA alignment and Phase 3 design remain the key swing factors.

03

What to watch

The article notes an FDA baseline FEV1 cutoff question and upcoming FDA discussions in Dec 2026 and Q1 2027; outcomes there could rapidly re-rate the launch timeline assumptions.

Relevance 6/10Novelty 5/10Timing: today, analyst price-target cut following the company’s Q3 results

Background

Connect Biopharma is developing rademikibart for acute asthma exacerbations and COPD, with mixed Phase 2 Seabreeze STAT results and planned FDA discussions for Phase 3 program design.

Company-level read

Ticker impact

$CNTBBearishMedium confidence
Context

Piper Sandler cut Connect Biopharma’s rademikibart launch timing to 2030 from 2029, lowering its price target to $5 from $7.

Expected impact

Likely pressure as traders price in a later rademikibart launch and weigh mixed Phase 2 asthma versus COPD readouts.

Evidence & confidence

The article’s actionable catalyst is the PT reduction tied to a specific launch-timing change, which typically affects near-term sentiment for pre-revenue biotech. It also flags upcoming FDA discussions that could swing expectations.

Market effects

Reinforces that pre-revenue biotech valuation is highly sensitive to modeled launch timing and FDA Phase 3 design alignment.

Limited, single-name analyst adjustment in US-listed small-cap biotech.

Low, no cross-market policy or sector-wide regulatory action described.

Counterpoint

COPD Phase 2 Seabreeze STAT results are described as strongly positive, which could offset the modeled asthma-driven delay if Phase 3 design is clarified favorably.

Key entities

  • Connect Biopharma Holdings Ltd

    NASDAQ-listed biotech developing rademikibart; subject of the price-target cut and described Phase 2/Phase 3 planning.

  • Piper Sandler

    Lowered CNTB price target to $5 from $7 while maintaining Overweight, citing launch timing shift to 2030.

  • Food and Drug Administration (FDA)

    Upcoming discussions expected to shape Phase 3 program design, including an asthma baseline FEV1 cutoff question.

Related articles

$CNTBMed

Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update – Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and c

$CNTBHighAI 9/10

Why is Connect Biopharma stock surging today?

Connect Biopharma (CNTB) stock rose 17.4% to $1.165 after positive Phase 2 trial results for its COPD treatment, rademikibart. The drug showed significant efficacy, reducing treatment failure rates and exacerbations. BTIG lowered its price target to $5.00 but maintained a Buy rating. Analysts generally remain positive, with a consensus price target of $6.14. The company plans to discuss Phase 3 development with the FDA. The broader market also gained due to softer inflation data.